Active Ingredient(s):Baricitinib FDA Approved: * May 31, 2018 Pharm Company: *ELI LILLY AND CO Category:Arthritis
Baricitinib, sold under the brand name Olumiant among others, is a drug for the treatment of rheumatoid arthritis (RA) in adults whose disease was not well controlled by tumor necrosis factor (TNF) inhibitors. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2. The drug is approved for medical use in the European Union and in the United States. An important side effec...
* May have multiple approval dates, manufacturers, or labelers.